Search Result "FLT3-ITD AML"
Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia
Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 18 Issue: 10 Year: 2018 Page: 1489-1494
Author(s): Nan Yang,Zhenyang Gu,Zhanxiang Liu,Wenrong Huang,Shuhong Wang,Lili Wang,Chunji Gao
Scaffold-hopping of Linifanib to Design 6-phenylisoxazolo[3,4-b]pyridin-3-amineDerivatives as FLT3 Inhibitors for Treating Acute Myeloid Leukemia
Journal: Letters in Drug Design & Discovery
Volume: 21 Issue: 10 Year: 2024 Page: 1833-1846
Author(s):
Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Journal: Current Cancer Therapy Reviews
Volume: 9 Issue: 3 Year: 2013 Page: 181-219
Author(s): Ugo Testa
Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Journal: Current Cancer Therapy Reviews
Volume: 4 Issue: 1 Year: 2008 Page: 31-49
Author(s): Ugo Testa
The Evolving AML Genomic Landscape: Therapeutic Implications
Journal: Current Cancer Drug Targets
Volume: 20 Issue: 7 Year: 2020 Page: 532-544
Author(s): Sachi Horibata,George Alyateem,Christin B. DeStefano,Michael M. Gottesman
Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Journal: Current Pharmaceutical Design
Volume: 10 Issue: 1 Year: 2004 Page: 1867-1883
Author(s): Dirk Schmidt-Arras, Joachim Schwable, Frank- D. Bohmer, Hubert Serve
FLT3 and Acute Myelogenous Leukemia: Biology, Clinical Significance and Therapeutic Applications
Journal: Current Pharmaceutical Design
Volume: 11 Issue: 2 Year: 2005 Page: 3449-3457
Author(s): A. S. Advani
The Role of FLT3 Kinase as an AML Therapy Target
Journal: Current Pharmaceutical Design
Volume: 18 Issue: 19 Year: 2012 Page: 2758-2765
Author(s): Michal Beffinger,Anna Skwarska
The Role of DNA Repair Pathways in AML Chemosensitivity
Journal: Current Drug Targets
Volume: 19 Issue: 10 Year: 2018 Page: 1205-1219
Author(s): Elizabeth A. Pearsall,Lisa F. Lincz,Kathryn A. Skelding
Developments of Fms-like Tyrosine Kinase 3 Inhibitors as AnticancerAgents for AML Treatment
Journal: Current Medicinal Chemistry
Volume: 31 Issue: 29 Year: 2024 Page: 4657-4686
Author(s):